Today in the face of illness, millions of people are confronted with diagnostic uncertainty. As patients and their physicians seek accurate diagnosis of their condition, precision diagnostics are playing important new roles in medicine, and are helping to inspire the growing presence of precision medicine today.
Navidea Biopharmaceuticals (NYSEMKT: NAVB) is a global leader in precision diagnostics which pinpoint molecular sites and pathways to identify the presence and status of disease. Through our innovative and flexible platforms and products, we are committed to improving diagnostic accuracy, empowering clinical decision-making and enhancing patient care. The Company focuses on the development and commercialization of innovative precision diagnostic agents that can and will make a difference for individuals – and families, physicians and care givers – touched by devastating conditions like cancer, dementia and movement disorders. Our mission is to bring next generation precision diagnostic agents to market so doctors and patients can readily access, and benefit from, cutting-edge diagnostic science.
For patients and physicians, we aspire to provide innovative medical imaging agents to improve patient care for serious diseases. For investors, we aim to deliver superior growth through our focus on our innovative imaging and imaging-related platforms and efficient business processes. For our employees, we provide a culture that focuses on the direct contributions our efforts make for the patients we serve and an innovative development environment for new breakthrough products.
Navidea’s products and pipeline include:
Lymphoseek®, a radiopharmaceutical agent for sentinel lymph node mapping for patients with several different types of solid tumor cancers. Lymphoseek was approved by the U.S. Food and Drug Administration in March 2013 and launched in May 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.The Company is planning an sNDA submission in 2013, and is awaiting MAA clearance by the EMA in Europe.
NAV4694 a powerful, second-generation PET imaging agent in Phase 3 development which may aid the differential diagnosis of mild cognitive impairment and dementia, including Alzheimer's disease, allowing patients to seek earlier treatment options.
NAV5001, a best-in-class SPECT imaging agent in Phase 3 development for the diagnosis of movement disorders, including Parkinson’s disease, and Dementia with Lewy Bodies.
RIGScanTM a tumor-specific targeting agent that holds great promise in detecting occult and metastatic cancer in patients with colorectal cancer and other adenocarcinomas.
The Manocept™ Technology Platform focused on inflammation via CD206-targeting of macrophages across a range of potential disorders including rheumatoid arthritis, lupus, Crohn’s disease, tuberculosis, vulnerable plaque and others.
Navidea has more than 40 employees worldwide with headquarters in Dublin, Ohio.